Who are DXM + Propofol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Midazolam+Ketamine Combination, Haloperidol + Ketamine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dxm-propofol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

DXM + Propofol — Competitive Intelligence Brief

DXM + Propofol (DXM + Propofol) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dissociative anesthetic combination. Area: Anesthesia.

marketed Dissociative anesthetic combination NMDA receptor (DXM); GABA-A receptor (propofol) Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

DXM + Propofol (DXM + Propofol) — Seoul National University Hospital. DXM (dextromethorphan) and propofol together provide dissociative anesthesia and analgesia through NMDA receptor antagonism and GABAergic potentiation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DXM + Propofol TARGET	DXM + Propofol	Seoul National University Hospital	marketed	Dissociative anesthetic combination	NMDA receptor (DXM); GABA-A receptor (propofol)
Midazolam+Ketamine Combination	Midazolam+Ketamine Combination	Universidad de Cartagena	marketed	Sedative-hypnotic and dissociative anesthetic combination	GABA-A receptor (midazolam); NMDA receptor (ketamine)
Haloperidol + Ketamine	Haloperidol + Ketamine	University Hospital, Basel, Switzerland	marketed	Antipsychotic + Dissociative anesthetic combination	Dopamine D2 receptor (haloperidol); NMDA glutamate receptor (ketamine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dissociative anesthetic combination class)

Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DXM + Propofol — Competitive Intelligence Brief. https://druglandscape.com/ci/dxm-propofol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab